Preeclampsia Drugs Market Outlook 2024: Exclusive Report By The Business Research Company | AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Preeclampsia Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.13 billion in 2023 to $1.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Market Segmentation:
The main types of preeclampsia drugs are mild preeclampsia and severe preeclampsia. Mild preeclampsia is a medical disorder that occurs in some pregnant women, usually after the 20th week of pregnancy. They are available for various treatments, such as medication to lower blood pressure (B.P.), corticosteroids and anticonvulsant medication and are administered through various routes, such as the oral route, the parenteral route and others. They are available in various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies and others and utilized by various end-users, such as hospitals, specialty clinics, diagnostic centers and others.

Major Driver - Rising Diabetes Cases In Pregnancy Fueling Growth In The Preeclampsia Drug Market
The rise in diabetes cases among pregnant women is expected to propel the growth of the preeclampsia drug market going forward. Diabetes is a metabolic disease that is chronic and characterized by high blood glucose (or blood sugar) levels. Preeclampsia is a harmful pregnancy condition with elevated blood pressure and organ damage. Metformin, a preeclampsia medicine, is widely used in pregnant women with preterm preeclampsia. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, the total incidence of gestational diabetes mellitus (GDM) was 20,865 cases, an increase of 6.56% in 2022. Therefore, the rise in diabetes cases among pregnant women will drive the preeclampsia drug market.

Competitive Landscape:
Major players in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Top Trend - Leading Companies In The Preeclampsia Medicine Market Pursuing Innovative Drug Solutions
Major companies in the preeclampsia medicine market are focusing on developing cutting-edge drug solutions to boost their market position. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, revealed that the Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for CBP-4888 Comanche's unique siRNA treatment to treat preeclampsia. CBP-4888 is a siRNA therapy given subcutaneously and reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta's overproduction of the protein sFLT1, which enters the mother's circulation, is the primary cause of preeclampsia. CBP-4888 can alleviate the symptoms of preeclampsia, such as high blood pressure and organ damage and may allow for the safe extension of pregnancy.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Preeclampsia Drugs Market Characteristics
3. Preeclampsia Drugs Market Trends And Strategies
4. Preeclampsia Drugs Market - Macro Economic Scenario
5. Preeclampsia Drugs Market Size And Growth
…..
27. Preeclampsia Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.